Business Description
Revance Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US7613301099
Description
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.47 | |||||
Equity-to-Asset | -0.26 | |||||
Debt-to-Equity | -3.79 | |||||
Debt-to-EBITDA | -1.93 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -6.25 | |||||
Beneish M-Score | -1.5 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 118.8 | |||||
3-Year EBITDA Growth Rate | 8.4 | |||||
3-Year EPS without NRI Growth Rate | 15.3 | |||||
3-Year FCF Growth Rate | 5.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 25.98 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 31.21 | |||||
9-Day RSI | 26.53 | |||||
14-Day RSI | 34.88 | |||||
6-1 Month Momentum % | 41.99 | |||||
12-1 Month Momentum % | -39.06 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.74 | |||||
Quick Ratio | 3.01 | |||||
Cash Ratio | 2.48 | |||||
Days Inventory | 257.39 | |||||
Days Sales Outstanding | 40.74 | |||||
Days Payable | 39.1 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.3 | |||||
Shareholder Yield % | -28.03 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 71.53 | |||||
Operating Margin % | -73.86 | |||||
Net Margin % | -117.88 | |||||
FCF Margin % | -85.78 | |||||
ROA % | -55.05 | |||||
ROIC % | -81.61 | |||||
3-Year ROIIC % | -44.17 | |||||
ROC (Joel Greenblatt) % | -230.67 | |||||
ROCE % | -59.49 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.97 | |||||
EV-to-EBIT | -3.06 | |||||
EV-to-EBITDA | -3.15 | |||||
EV-to-Revenue | 3.29 | |||||
EV-to-Forward-Revenue | 1.98 | |||||
EV-to-FCF | -3.84 | |||||
Earnings Yield (Greenblatt) % | -32.68 | |||||
FCF Yield % | -38.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Revance Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 225.732 | ||
EPS (TTM) (€) | -2.973 | ||
Beta | 1.76 | ||
Volatility % | 117.17 | ||
14-Day RSI | 34.88 | ||
14-Day ATR (€) | 0.125768 | ||
20-Day SMA (€) | 5.1175 | ||
12-1 Month Momentum % | -39.06 | ||
52-Week Range (€) | 2.14 - 9.95 | ||
Shares Outstanding (Mil) | 104.18 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Revance Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Revance Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Revance Therapeutics Inc Frequently Asked Questions
What is Revance Therapeutics Inc(STU:RTI)'s stock price today?
When is next earnings date of Revance Therapeutics Inc(STU:RTI)?
Does Revance Therapeutics Inc(STU:RTI) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |